- Home
- NMCO vs AUTL Comparison
NMCO vs AUTL Comparison
Compare NMCO & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMCO
- AUTL
- Stock Information
- Founded
- NMCO 2019
- AUTL 2014
- Country
- NMCO United States
- AUTL United Kingdom
- Employees
- NMCO N/A
- AUTL N/A
- Industry
- NMCO Finance/Investors Services
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMCO Finance
- AUTL Health Care
- Exchange
- NMCO Nasdaq
- AUTL Nasdaq
- Market Cap
- NMCO 560.1M
- AUTL 625.4M
- IPO Year
- NMCO N/A
- AUTL 2018
- Fundamental
- Price
- NMCO $10.33
- AUTL $1.50
- Analyst Decision
- NMCO
- AUTL Strong Buy
- Analyst Count
- NMCO 0
- AUTL 5
- Target Price
- NMCO N/A
- AUTL $9.12
- AVG Volume (30 Days)
- NMCO 207.6K
- AUTL 2.8M
- Earning Date
- NMCO 01-01-0001
- AUTL 08-12-2025
- Dividend Yield
- NMCO 5.43%
- AUTL N/A
- EPS Growth
- NMCO N/A
- AUTL N/A
- EPS
- NMCO N/A
- AUTL N/A
- Revenue
- NMCO N/A
- AUTL $29,934,000.00
- Revenue This Year
- NMCO N/A
- AUTL $634.25
- Revenue Next Year
- NMCO N/A
- AUTL $93.16
- P/E Ratio
- NMCO N/A
- AUTL N/A
- Revenue Growth
- NMCO N/A
- AUTL 185.17
- 52 Week Low
- NMCO $8.52
- AUTL $1.11
- 52 Week High
- NMCO $11.64
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- NMCO 56.57
- AUTL 25.52
- Support Level
- NMCO $10.08
- AUTL $1.53
- Resistance Level
- NMCO $10.40
- AUTL $1.64
- Average True Range (ATR)
- NMCO 0.08
- AUTL 0.15
- MACD
- NMCO 0.02
- AUTL -0.04
- Stochastic Oscillator
- NMCO 78.13
- AUTL 1.48
About NMCO Nuveen Municipal Credit Opportunities Fund
Nuveen Municipal Credit Opps Fund is a closed-end fund. The fund's objective is to provide a high level of current income exempt from regular U.S. federal income tax and secondarily, total return. It invests in high yielding, low-to medium-quality municipal securities and uses leverage.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.